Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
29 March 2018Website:
http://www.cogentbio.comNext earnings report:
08 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 20:38:17 GMTDividend
Analysts recommendations
Institutional Ownership
COGT Latest News
Cogent (COGT) announces a positive FDA meeting and alignment on MS2D2, a novel patient-reported outcome measure for the SUMMIT study. The company's shares rise on the news.
Patients treated with 100 mg bezuclastinib showed substantial reduction in their most severe symptoms and mast cell reactions
WALTHAM, Mass. and BOULDER, Colo., May 23, 2024 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Cole Pinnow as Chief Commercial Officer. Mr. Pinnow is a leader in the biopharmaceutical industry with an impressive track record in commercial strategy, including several successful product launches. At Cogent, he will be responsible for building and leading the commercial team including sales, marketing, access, and commercial operations. A key priority will be preparing the company for the potential commercial launch of bezuclastinib, for patients with systemic mastocytosis (SM) or Gastrointestinal Stromal Tumors (GIST).
Having ended 2022 on a low note, U.S. market indexes have overall shown stronger performances so far in 2023.
WALTHAM, Mass. and BOULDER, Colo., April 12, 2023 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced its participation in the following upcoming virtual investor conferences:
What type of business is Cogent Biosciences?
Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
What sector is Cogent Biosciences in?
Cogent Biosciences is in the Healthcare sector
What industry is Cogent Biosciences in?
Cogent Biosciences is in the Biotechnology industry
What country is Cogent Biosciences from?
Cogent Biosciences is headquartered in United States
When did Cogent Biosciences go public?
Cogent Biosciences initial public offering (IPO) was on 29 March 2018
What is Cogent Biosciences website?
https://www.cogentbio.com
Is Cogent Biosciences in the S&P 500?
No, Cogent Biosciences is not included in the S&P 500 index
Is Cogent Biosciences in the NASDAQ 100?
No, Cogent Biosciences is not included in the NASDAQ 100 index
Is Cogent Biosciences in the Dow Jones?
No, Cogent Biosciences is not included in the Dow Jones index
When does Cogent Biosciences report earnings?
The next expected earnings date for Cogent Biosciences is 08 August 2024